Incruse får generelt tilskud

Incruse indeholder umeclidinium og anvendes til behandling af kronisk obstruktiv lungesygdom (KOL).

September 18, 2014 5:00 AM

Sundhedstyrelsen vurderer, at lægemidlets pris står i et rimeligt forhold til dets behandlingsmæssige værdi, når behandling med Incruse stilles over for behandling med andre langtidsvirkende muskarinreceptor-antagonister.

Incruse bliver omfattet af den igangværende revurdering af tilskud for lægemidler mod astma og KOL i ATC-gruppe R03.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.